Age-Onset-Related Particularities of Pediatric MS—Understanding the Spectrum: A Tertiary Center Experience
Authors:
- Alice Denisa DicăAlice Denisa Dică
- Dana CraiuDana Craiu
- Florentina Ionela LincaFlorentina Ionela Linca
- Magdalena BudișteanuMagdalena Budișteanu
- Catrinel IliescuCatrinel Iliescu
- Carmen SanduCarmen Sandu
- Cristina PomeranCristina Pomeran
- Diana BârcăDiana Bârcă
- Niculina ButoianuNiculina Butoianu
- Carmen BurloiuCarmen Burloiu
- Ioana MinciuIoana Minciu
- Ina Ofelia FocșaIna Ofelia Focșa
Open Access
Abstract
Background: Pediatric-onset multiple sclerosis (POMS) is a rare and heterogeneous condition, with clinical features, progression, and therapeutic response varying significantly according to age at onset. Early-onset MS (12 years) forms. Methods: We conducted a retrospective analysis of medical records from 120 pediatric patients diagnosed with MS at a tertiary neurology center between 2018 and 2024. Patients were grouped by age at onset and assessed for clinical presentation, number and timing of relapses, EDSS scores, imaging findings, and treatment patterns. Results: Early-onset MS was associated with atypical symptoms, delayed diagnosis, more frequent relapses, and multifocal brainstem and cerebellar involvement. The diagnosis was significantly delayed in younger children compared to adolescents. EDSS scores tended to remain stable in the first 2–3 years, but early-onset patients showed a notable decline after the fourth year. While most patients received disease-modifying therapies, high-efficacy agents were underused due to age-related restrictions. Intermediate-onset patients presented overlapping features of both early and late-onset MS and had the highest proportion of fully preserved motor function (EDSS 0) at the end of follow-up. MRI findings revealed more extensive and confluent lesions in younger patients, particularly in the first two years after onset. Conclusions: Age at disease onset is a key determinant of clinical course and treatment response in pediatric MS. Early recognition and timely initiation of appropriate therapy—especially high-efficacy agents—may improve outcomes and reduce long-term disability. Further multicenter studies with standardized imaging and cognitive assessment protocols are needed to optimize care for this vulnerable population.Keywords
This publication has 61 references indexed in Scilit:
- Radiological features in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease—diagnostic criteria and lesion dynamicsPediatric Radiology, 2024
- Neuropsychological performances, quality of life, and psychological issues in pediatric onset multiple sclerosis: a narrative reviewNeurological Sciences, 2023
- Treatment of multiple sclerosis in children: A brief overviewClinical Immunology, 2022
- Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying TreatmentCNS Drugs, 2021
- White matter correlates of slowed information processing speed in unimpaired multiple sclerosis patients with young age onsetBrain Imaging and Behavior, 2020
- Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosisBrain, Behavior, and Immunity, 2020
- ADHD pathogenesis in the immune, endocrine and nervous systems of juvenile and maturating SHR and WKY ratsPsychopharmacology, 2019
- Electroconvulsive Therapy in Women: A Retrospective Study from a Mental Health Hospital in TurkeyPsychiatric Quarterly, 2016
- Quality of life and cognitive functions in early onset multiple sclerosisEuropean Journal of Paediatric Neurology, 2016
- Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple SclerosisArchives of Neurology, 2009